Asia

Hospital Management Asia 2019, the annual event for Asian healthcare leaders, will be held September 11-12, 2019, at the National Convention Centre of Vietnam.

Takeda will release complete Phase III data at a future scientific conference and is planning on seeking regulatory approval for the investigational formulation.

Eisai Co., Ltd. announced the presentation and discussion about the treatment, including oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat(1) research data on Alzheimer’s disease(AD), were given in the AAIC’s Focused Topic Session “Discussion of BACEi Trial Findings: Challenges and Opportunities” at the Alzheimer’s Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019.

In Cerebrospinal Fluid and the Identification of a Target Engagement Biomarker for the New Anti-Tau Antibody E2814 at Alzheimer’s Association International Conference (AAIC) 2019

It was a big week for Alzheimer’s research as researchers from around the world descended on Los Angeles to attend the Alzheimer’s Association International Conference (AAIC) this week. Here’s a look at some of the stories you may have missed.

Without Significant Effects on Synaptic Function in Brain by Spinal Densitiy Evaluation at Effective Dose to Decrease Amyloid Beta Level in Cerebrospinal Fluid at Alzheimer’s Association International Conference (AAIC) 2019

Bridge Biotherapeutics licensed out its BB-877 to Boehringer Ingelheim for a total deal of about $1.75 billion. This is the second large deal for fibrotic diseases Boehringer Ingelheim inked since the beginning of the month.

In May, the company sold off assets worth $5.7 billion and now, the company is looking to sell more.

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Co. have teamed up to study the most common type of metastatic colorectal cancer (mCRC).

Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration.